ProMetic Life Sciences Inc.: Lancet Study Reports 'Significant Breakthrough' In Quest To Prevent vCJD Transmission Through Blood Tranfusion

Published: Dec 22, 2006

CAMBRIDGE, UNITED KINGDOM AND LILLE, FRANCE -- (MARKET WIRE) -- December 21, 2006 -- Pathogen Removal and Diagnostic Technologies Inc. (PRDT), a joint-venture between ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") and The American Red Cross (ARC), along with PRDT's co-development, commercial and manufacturing partner, MacoPharma, announce that a study published today in the Lancet (Gregori L, Gurgel P, Lathrop J et al) reveals that PRDT's prion capture affinity resin incorporated into the P-CAPTĀ® prion capture filter removes, to the limit of detection, the infectivity that is naturally present in blood during infections by Transmissible Spongiform Encephalopathies (TSE's), such as variant Creutzfeldt-Jakob disease (vCJD) and that it prevents the transmission of infection by contaminated blood.

Back to news